AI Article Synopsis
- Researchers developed new star-shaped polymers combining a triphenylamine-based iridium complex as the orange core with blue-emitting poly(9,9-dihexylfluorene) chains for white polymer light-emitting diodes (WPLEDs).
- By adjusting the amount of orange phosphor, the polymers achieve partial energy transfer and charge trapping, creating white light emission.
- The single-layer WPLEDs showed a maximum current efficiency of 1.69 cd A(-1) with CIE coordinates close to pure white light, marking a significant advancement as the first star-shaped polymer with both fluorescent and phosphorescent components.
Article Abstract
A series of new star-shaped polymers with a triphenylamine-based iridium(III) dendritic complex as the orange-emitting core and poly(9,9-dihexylfluorene) (PFH) chains as the blue-emitting arms is developed towards white polymer light-emitting diodes (WPLEDs). By fine-tuning the content of the orange phosphor, partial energy transfer and charge trapping from the blue backbone to the orange core is realized to achieve white light emission. Single-layer WPLEDs with the configuration of ITO (indium-tin oxide)/poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS)/polymer/CsF/Al exhibit a maximum current efficiency of 1.69 cd A(-1) and CIE coordinates of (0.35, 0.33), which is very close to the pure white-light point of (0.33, 0.33). To the best of our knowledge, this is the first report on star-shaped white-emitting single polymers that simultaneously consist of fluorescent and phosphorescent species.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/marc.201400420 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chong Qing, China.
Background: Alzheimer's disease (AD) frequently coexists with cerebral small vessel disease (CSVD) is common in the aging population, yet the underlying mechanisms are not yet fully understood. Both long-term blood pressure variability (BPV) and plasma neurofilament light (PNFL) were identified as potential biomarkers for AD and CSVD. This study aims to understand the mechanisms of comorbidity between AD and CSVD by investigating the associations among BPV, PNFL, and comorbidity.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Background: A significant proportion of individuals preserve cognitive function despite meeting neuropathological criteria for Alzheimer's disease (AD) at autopsy, known as cognitive resilience. We aimed to define the molecular and cellular signatures of cognitive resilience against AD.
Method: We integrated multi-modal data from the Religious Order Study and Memory and Aging Project (ROSMAP), including bulk (n = 631) and multi-regional single nucleus (n = 48) RNA sequencing.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA.
Background: Vascular cognitive impairment/dementia (VD) is the second most prevalent cause of dementia following Alzheimer's disease (AD). VD is characterized by the progression of white matter hyperintensity burden (WMH) and associated neurodegeneration. GFAP, a biomarker for reactive astrogliosis, is associated with Aβ pathology and mediates tau-pathology in preclinical AD.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Center for Translational & Computational Neuroimmunology, Columbia University Irving Medical Center, New York, NY, USA.
Background: Stage III activated microglia have been associated with Alzheimer's Disease (AD) and cognitive decline. Separately, recent single-cell RNA-sequencing revealed CD74 as a marker gene that is enriched in immunologically active microglial subtypes associated with AD.
Method: Post mortem tissue sections from the dorsolateral prefrontal cortex were stained simultaneously for (1) CD74, (2) IBA1 (a general microglial marker that outlines cellular processes), and (3) phosphoTau (AT8 antibody) to locate Tau proteinopathy.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, New York, NY, USA.
Background: Blood-based biomarkers may aid in the diagnosis of Alzheimer's Disease (AD), but their contribution may be confounded by the presence of multiple chronic conditions and have not been well-tested in community populations. In the current study, we aimed to determine whether blood-based biomarkers can aid in refining a multi-ethnic, urban clinically diagnosed AD community-based cohort.
Method: We included 546 individuals in the Washington Heights, Hamilton Heights, and Inwood Columbia Aging Project (WHICAP) study in this cross-sectional study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!